With expectations of earnings improvement and the Legend Biotech IPO, can Genscript break through the $13 mark?

As of April 2, Genscript (01548) closed at $12.24, up 3.29%, with a turnover of 134 million. The stock price rebounded from its recent low over the past five trading days, showing some technical improvement. Observing the technical state, the current stock price has regained the 10-day line ($11.15) and the 30-day line ($11.42), but remains pressured near the 60-day line ($12.30), placing it at a key short-term technical juncture. In terms of technical indicators, the RSI has risen to 60, entering a neutral-to-strong region; the VR volume ratio indicator shows a 'buy' signal, reflecting increased buying support at lower levels. However, both the stochastic oscillator and Williams %R indicators have turned to overbought sell signals, while the CCI indicator is also in an overbought condition, indicating that upward momentum has been somewhat exhausted after the sharp rise, necessitating technical consolidation. Both the MACD signal and Bollinger Bands remain in 'buy' mode, with the overall technical indicator summary being 'neutral' with a strength of 10. This trend-positive but short-term oscillation-overbought structure indicates the stock is in a critical direction-choosing phase following the rebound. Previous technical analysis pointed out that Genscript had formed a 'descending triangle breakout' pattern, with the stock breaking down at the triangle's endpoint, forming a downtrend with soft technical trends. However, the recent significant rebound from the lows has weakened the relevance of this bearish signal.

In terms of market news, Genscript's recent share price rebound has mainly benefited from improved 2025 financial performance and positive news about its associated company, Legend Biotech. The company achieved revenue from continuing operations of approximately $960 million in 2025, representing a year-on-year increase of 61.4%; adjusted net profit was approximately $230 million, marking a substantial year-on-year growth of 285%, with a clearer path for profit recovery. Additionally, there are market rumors that Legend Biotech plans to list in Hong Kong this year, raising $300 to $400 million. Genscript holds about 47.2% of its shares, and if the listing succeeds, it will help unlock the value of the cell therapy business.

From a key position analysis, initial support below is seen at $11.40, which serves as the 10-day line and a short-term support zone during the recent rebound. If this level is breached, the next support lies at $11.00. On the resistance side, the first hurdle is at $13.00, which was a previous high point during the rebound in the prior downtrend. A breakout above this level could lead to a target of $13.70. The overall probability of an upward move is 54%, relatively high among the stocks provided, indicating that conditions for a technical rebound are relatively mature, but attention should be paid to the consolidation pressure brought by short-term overbought conditions.

In terms of product deployment, if investors believe that Genscript can hold steady above the $11.40 support and further challenge the resistances at $13.00 and $13.70, they may consider two call warrants. Huatai Call Warrant (23517) $HUGSBIO@EC2608A.C (23517.HK)$ Strike price $17.50, effective leverage 4.0x, premium 51.0%, last trading day August 25, 2026, implied volatility 77.4%, street ratio 1.22%. This product offers superior terms compared to similar products in terms of effective leverage, premium, time to maturity, and implied volatility, with better short-term performance, registering a gain of approximately 23% over two days, showing higher sensitivity to changes in the underlying stock price.

Morgan Stanley Call Warrant (25356) $JPGSBIO@EC2608A.C (25356.HK)$The exercise price is 17.51 yuan, effective leverage is 4.0 times, premium is 51.2%, the last trading day is August 18, 2026, implied volatility is 80.4%, and the street ratio is 0.41%. This product has an extremely low street ratio, indicating less market position pressure, making it suitable for investors looking to avoid high street products. The exercise prices of both products are at a certain distance from the upper resistance level of 13.7 yuan, reflecting that the product design expects the stock price to rise significantly before entering an in-the-money state. Traders should be mindful of the impact of time decay when deploying.

Overall, Genscript is currently in a phase of 'technical rebound and short-term overbought.' In the short term, the stock is likely to fluctuate within the range of 11.4 yuan to 13 yuan. The ideal strategy would be to wait for a clear breakout above the 13 yuan resistance or confirmation of support at 11.4 yuan before taking a directional position. If trading within this range, strict position control and reasonable stop-loss levels must be maintained.

Interactive Q&A:

Do you think Genscript can break through the 13 yuan resistance in the short term and continue to rise?

A. It can break through; improved earnings and the anticipated Legend Biotech listing will drive the stock price.

B. It will struggle to break through; short-term overbought conditions will trigger technical consolidation.

C. First consolidate with fluctuations between 11.5 yuan and 13 yuan.

Feel free to share your thoughts in the comments section.

#GenScript #01548 #TechnicalAnalysis #SupportLevel #ResistanceLevel #Warrant #CallWarrant #PharmaceuticalStock #LegendBiotech #HKExWarrantJenny

Warm Reminder: This article does not constitute any investment advice. It is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive evaluation of asset performance should be made using other data, and trading decisions should not be based solely on this article. Please note that past performance is not indicative of future results. Follow HK Stocks Warrants Jenny for more professional insights.

$Hang Seng Index (800000.HK)$ $Hang Seng TECH Index (800700.HK)$ $Hang Seng China Enterprises Index (800100.HK)$

40K Views